未登录

O

Outi Varpuluoma

University of Oulu

H指数:8

被引数:429

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Genes associated with immune response are upregulated in clinically healthy skin of patients with gliptin-associated bullous pemphigoid

与免疫反应相关的基因在gliptin相关大疱性类天疱疮患者的临床健康皮肤中上调

Journal of Investigative Dermatology

IF5.7

2026-02-130

OAAI

Treatment of bullous pemphigoid with methotrexate is associated with a decreased mortality risk

使用甲氨蝶呤治疗天疱疮与大疱性类天疱疮相关联，并伴随有降低死亡风险。

BRITISH JOURNAL OF DERMATOLOGY

IF9.6

2025-05-050

PRE

Widespread Rash with Localized Sparing: A Quiz

ACTA DERMATO-VENEREOLOGICA

IF3.7

2025-01-010

OAAI

Type 2 Diabetes and its Treatment with Linagliptin are both Associated with Elevated Mortality in Bullous Pemphigoid

ACTA DERMATO-VENEREOLOGICA

IF3.7

2024-09-041

OAAI

Epidemiology and Comorbidities of Mucous Membrane Pemphigoid: A National Cohort Study

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2024-09-010

OAAI

Solid and hematological malignancies in patients with bullous pemphigoid: A national cohort study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2024-02-012

OAAI

Accurate diagnosis of bullous pemphigoid requires multiple health care visits

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-11-273

OAAI

Bullous pemphigoid and neuropsychiatric medications: An influence of drugs or of underlying conditions?

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2023-03-010

OAAI

Dipeptidyl Peptidase 4 Inhibitor-Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2023-01-013

OAAI

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-07-253

OAAI

Ulcerative Tuberculosis in a Patient Treated with Adalimumab

ACTA DERMATO-VENEREOLOGICA

IF3.7

2022-04-270

OAAI

GLP-1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2021-12-015

OAAI

Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2019-09-010

OAAI

Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: A case-control study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2019-07-0113

OAAI

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

FRONTIERS IN IMMUNOLOGY

IF5.9

2019-06-0489

OAAI

Reply to: Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid''

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2019-06-010

PREAI

Dermatitis Herpetiformis and Celiac Disease Increase the Risk of Bullous Pemphigoid

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2019-03-0116

OAAI

Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid

格列汀相关的大疱性类天疱疮和二肽基Peptidase-4/CD26在大疱性类天疱疮中的表达

ACTA DERMATO-VENEREOLOGICA

IF3.7

2019-01-0138

OAAI

Reply to: Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study'

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2018-12-010

OAAI

Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2018-12-0133

OAAI